FDA-cleared profile

InferRead Lung CT.AI

Infervision Medical Technology Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.

Clinical role
Adjunctive detection, localization, measurement and longitudinal comparison
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.
  • Who uses it?Intended users: Radiologists
  • What does the software produce?Output: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
  • What is its most important limitation?Key limitation: Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.

Clinical takeaway. Clinical role: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.

Evidence takeaway. Evidence from the reviewed source record: K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Adjunctive detection, localization, measurement and longitudinal comparison
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult chest CT review; asymptomatic patients aged at least 55 years.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Radiologists
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Adjunctive information only; not for use without the original CT series. Both lungs must be in view and the labeled age, asymptomatic population and nodule-size restrictions apply.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.
  • Exact FDA submission
  • Checked 2026-09-05

Refines baseline ACR 214 cases: 98+94+22 is a sum of test cohorts, not a verified unique-patient total or a new reader diagnostic-sensitivity cohort.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K240554 reports separate standalone cohorts for longitudinal nodule matching (98 cases), lobar location (94 scans) and lung/lobe segmentation (22 cases). Nodule detection/segmentation consistency with the predicate was assessed separately.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Refines baseline ACR 214 cases: 98+94+22 is a sum of test cohorts, not a verified unique-patient total or a new reader diagnostic-sensitivity cohort.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Matching, lobar localization and Dice segmentation results are not diagnostic nodule-detection sensitivity; no exact-release estimate promoted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-release specificity estimate established from the reviewed new-feature tests.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K240554 longitudinal nodule matching validation

  • DesignStandalone comparison of automatic matching against reference nodule pairs
  • Population98 screening cases with 206 nodule pairs
  • Scopeexact submission
  • Tested versionInferRead Lung CT.AI K240554
  • Samplen=98
  • IndependenceSponsor or vendor study

K240554

K240554 lobar localization validation

  • DesignStandalone nodule lobar-location evaluation
  • Population94 CT scans containing 188 nodules
  • Scopeexact submission
  • Tested versionInferRead Lung CT.AI K240554
  • Samplen=94
  • IndependenceSponsor or vendor study

K240554

K240554 lung/lobe segmentation validation

  • DesignStandalone segmentation overlap comparison
  • Population22 cases with 110 lung lobes
  • Scopeexact submission
  • Tested versionInferRead Lung CT.AI K240554
  • Samplen=22
  • IndependenceSponsor or vendor study

K240554

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

No product-specific code

National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established

Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10

The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Chest CT in DICOM format with both lungs in the field of view; original CT series must be available. Prior and current examinations support temporal comparison.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · InferRead Lung CT.AI: K240554 clearance and summary

  2. Routing

    Source context, not route validation: DICOM CT processing with temporal registration/nodule matching and manual adjustment of registration results.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · InferRead Lung CT.AI: K240554 clearance and summary

  3. AI processing

    Source context, not route validation: The exact FDA package describes InferRead Lung CT.AI as a dedicated post-processing application that can be installed in a healthcare facility or a cloud-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "a dedicated post-processing application that generates CADe marks as an overlay on original CT scans. The software can be installed in a healthcare facility or a cloud-based platform". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · InferRead Lung CT.AI: K240554 clearance and summary

  4. Returned objects

    Source context, not route validation: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · InferRead Lung CT.AI: K240554 clearance and summary

  5. Viewer/worklist/report

    Unresolved route: CADe overlays and nodule segmentation, longest/shortest and mean diameters, volume, mean HU density, lobar location and prior/current nodule matching with increased, decreased, new, disappeared or unchanged status.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · InferRead Lung CT.AI: K240554 clearance and summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes InferRead Lung CT.AI as a dedicated post-processing application that can be installed in a healthcare facility or a cloud-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "a dedicated post-processing application that generates CADe marks as an overlay on original CT scans. The software can be installed in a healthcare facility or a cloud-based platform". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
DICOM CT processing with temporal registration/nodule matching and manual adjustment of registration results.
  • Exact FDA submission
  • Checked 2026-09-05
Training
The vendor's global V2 labeling describes hospital-administrator training and necessary operator/user training before use.
  • Product family
  • Checked 2026-09-05

Global V2 labeling is not linked to the exact US K240554 build or a priced training contract.

Monitoring
Global V2 warnings ask users to report missed/misdiagnoses and serious incidents and to verify patient labels when identifying information is absent.
  • Product family
  • Checked 2026-09-05

User reporting instructions are not evidence of automated clinical drift monitoring.

DICOM and longitudinal review

CT DICOM input with prior/current nodule matching and manual registration adjustment.

exact submission · checked 2026-09-05

Family safety workflow

Global V2 labeling calls for user training, patient-label verification and incident reporting.

product family · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240554
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Controlled CT/CTA category; this does not add a separate CTA indication.

Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
22Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Stored metadata for Clinical Validation of InferRead Lung CT.AI screened. Live registry page returned only a shell and no readable study details. No exact K240554 linkage or trial results promoted; full record review remains unresolved. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor instructions for use, stored candidate metadata, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    Reviewed labeling and FDA materials do not establish license, hosting, interface or service costs.

  • Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission

    Per-exam versus site licensing and cloud/on-site terms remain unresolved.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    Exact-release hosting geography, access controls, retention and scoped security assurance remain unverified.

  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. InferRead Lung CT.AI: K240554 clearance and summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: purpose, clinicalUse, modality, anatomy, input, output, limitations, deployment, integration, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. InferRead Lung CT.AI model card (K240554)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. InferRead CT Lung V2 intended use and warnings

    Infervision - Accessed 2026-09-05

    Scope: productFamilyContext, training, monitoring, implementationCapabilities

  8. CMS National Coverage Determination 210.14: Lung Cancer Screening with Low Dose Computed Tomography (LDCT)

    Centers for Medicare & Medicaid Services (Medicare Coverage Database) - Accessed 2026-10-25

    Scope: reimbursement, coverage, payerPolicy

Research history

  1. K240554 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K213713

AI-Rad Companion (Pulmonary)

Siemens Healthcare GmBh

AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2022-08-11
FDA-cleared K231157

syngo.CT Lung CAD (Version VD30)

Siemens Healthcare GmbH

Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2023-07-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history